This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Should You Invest in the Health Care Select Sector SPDR ETF (XLV)?
by Zacks Equity Research
Sector ETF report for XLV
Should You Invest in the iShares U.S. Healthcare ETF (IYH)?
by Zacks Equity Research
Sector ETF report for IYH
Top Cancer Stocks to Supercharge Your 2025 Portfolio
by Kinjel Shah
Pfizer, Novartis and Fate Therapeutics are making bold oncology moves as demand surges for next-gen cancer therapies.
Have Skyrizi and Rinvoq Successfully Saved AbbVie From Humira LoE?
by Sundeep Ganoria
ABBV eyes $24.7 billion from Skyrizi and Rinvoq in 2025 as ex-Humira growth offsets sharp sales drop post-U.S. patent loss.
Pfizer Stock Down Almost 11% YTD: Should You Buy the Dip?
by Kinjel Shah
PFE lags the market as COVID sales drop and patent losses loom, but new drugs and cost cuts may fuel a comeback.
Eli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.
Is Novo Nordisk's Next Generation Obesity Pipeline a Game Changer?
by Zacks Equity Research
NVO advances obesity pipeline with CagriSema and Amycretin while expanding through major deals amid rising competition.
REGN Strengthens Obesity Pipeline: Will the Move Revive the Stock?
by Zacks Equity Research
REGN inks a $2B-plus obesity drug deal with Hansoh, aiming to expand its pipeline amid slumping Eylea sales and pipeline setbacks.
Should You Invest in the Vanguard Health Care ETF (VHT)?
by Zacks Equity Research
Sector ETF report for VHT
Weight Loss Drug ETF (THNR) Hits New 52-Week High
by Sanghamitra Saha
THNR hits a 52-week high, fueled by gains in Eli Lilly and Novo Nordisk -- could the rally still have legs?
Pharma Stock Roundup: LLY's New Deal, GSK & SNY's Pipeline Updates
by Kinjel Shah
LLY to acquire SiteOne for up to $1 billion. GSK's antibiotic study ends early for efficacy. MRNA loses H5 flu vaccine funding, while SNY sees mixed COPD data.
PFE or LLY: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
PFE vs. LLY: Which Stock Is the Better Value Option?
AbbVie Stock Down Around 13% in 3 Months: Time to Buy the Dip?
by Kinjel Shah
ABBV drops 12.6% in three months, but rising Skyrizi and Rinvoq sales, pipeline strength, and 2025 growth outlook support staying invested.
Eli Lilly to Expand Pain Pipeline With $1B SiteOne Buyout Offer
by Zacks Equity Research
LLY inks $1B deal to acquire SiteOne, adding phase II-ready pain drug STC-004 to strengthen its neuroscience pipeline.
Eli Lilly vs. AstraZeneca: Which Pharma Powerhouse is the Better Buy?
by Kinjel Shah
Lilly dominates GLP-1 market but faces near-term headwinds, while AstraZeneca boasts steady growth, rising estimates and a higher dividend yield.
Novo Nordisk vs. Viking Therapeutics: Which GLP-1 Stock Has More Upside?
by Sundeep Ganoria
With VKTX surging on clinical results and NVO investing to cement market share, investors face a high-stake GLP-1 showdown.
RXRX vs. SDGR: Which AI-Powered Drug Discovery Stock Has More Upside?
by Ahan Chakraborty
Recursion Pharmaceuticals and Schrodinger leverage their respective AI drug discovery platforms to potentially develop distinguished therapeutic candidates.
Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Zacks.com users have recently been watching Lilly (LLY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
3 Stocks Targeting Weight Loss Market With Cannabinoid-Based Therapies
by Sundeep Ganoria
NVO, CRBP and SKYE are tapping into the booming obesity market with novel CBD-based therapies, offering alternatives amid intensifying GLP-1 competition.
The Zacks Analyst Blog Highlights Eli Lilly, GE Aerospace and Amgen
by Zacks Equity Research
Zacks highlights LLY, GE, and AMGN as top picks, citing strong demand, product pipelines, and defense tailwinds despite some pricing and margin pressures.
Top Analyst Reports for Eli Lilly, GE Aerospace & Amgen
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), GE Aerospace (GE) and Amgen Inc. (AMGN).
Sanofi to Join Alzheimer's Space With Vigil Neuroscience Buyout
by Zacks Equity Research
SNY inks an agreement to acquire VIGL and its pipeline candidate VG-3927, which is being developed to treat Alzheimer's disease.
AstraZeneca Stock Declines 6% in 3 Months: Time to Buy the Dip?
by Kinjel Shah
AZN's key drugs like Lynparza, Tagrisso, Imfinzi, Ultomiris and Fasenra are likely to drive sales in 2025.
AMGN Down 10% in 3 Months: How to Play the Stock as Tariff Woes Linger
by Kinjel Shah
AMGN's consistent top-line growth, an interesting pipeline and rising estimates are good enough reasons to stay invested in the stock for now.
Should You Invest in the VanEck Pharmaceutical ETF (PPH)?
by Zacks Equity Research
Sector ETF report for PPH